LIU NINGSHU,HAIKE KATJA,PAUL JULIANE,WENGNER ANTJE MARGRET
申请号：
IN8757/DELNP/2015
公开号：
IN2015DN08757A
申请日:
2015.09.24
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
use of a 2 3 dihydroimidazo[l 2 c]quinazoline compound or of a pharmaceutical composition containing same as a sole active agent or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more fu rther active agents for the preparation of a medicament for the treatment or prophylaxis of non Hodgkin s lymphoma (NHL) particularly 1st line 2nd line relapsed refractory indolent or agressive non Hodgkin s lymphoma (NHL) in particular follicular lymphoma (FL) chronic lymphocytic leukaemia (CLL) marginal zone lymphoma (MZL) diffuse large B cell lymphoma (DLBCL) mantle cell lymphoma (MCL) transformed lymphoma (TL) or peripheral T cell lymphoma (PTCL) combinations of a) said compound and b) one or more further active agents a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non Hodgkin s lymphoma (NHL) particularly 1st line 2nd line relapsed refractory indolent or agressive non Hodgkin s lymphoma (NHL) in particular follicular lymphoma (FL) chronic lymphocytic leukaemia (CLL) marginal zone lymphoma (MZL) diffuse large B cell lymphoma (DLBCL) mantle cell lymphoma (MCL) transformed lymphoma (TL) or peripheral T cell lymphoma (PTCL) a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents use of biomarkers involved in the modification of the expression of PI3K isoforms BTK and IKK BCR activation BCR downstream activation of NFKB pathway c Myc EZH2 for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance and a method of determining the level of a component of one or more of the expression of PI3K isoforms BTK and IKK„ BCR activation BCR downstream activation of NFKB pathway c Myc EZH2.
